Agenus swings to Q2 FY26 net loss of $0.6 million; revenue rises 34.24% to $34.5 million year-over-year

• Agenus posted Q2 revenue of $34.5 million, up 34.24% from $25.7 million a year earlier.
• Operating income was $11.3 million, swinging from an operating loss of $16.7 million in Q2 2025.
• Net income was a loss of $0.6 million, improving from a net loss of $30 million a year earlier.
• Cash and cash equivalents ended Q2 at $18.7 million; a July private placement added about $85 million in gross cash proceeds.
• Management said the financing supports the planned Phase 3 ROBBIN trial of BOT+BAL, with first patient dosing expected in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.